title: Insulin-like growth factor 1 receptor inhibitors: where do we come from? What are we? Where are we going?
authors.affiliation: Division of Hematology-Medical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.
authors.forename: Bartosz
authors.initials: B
authors.lastname: Chmielowski
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001859:Bone Neoplasms / Q000188:drug therapy*; D006801:Humans; D017526:Receptor, IGF Type 1 / Q000276:immunology*; D012512:Sarcoma, Ewing / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017526:Receptor, IGF Type 1; C551399:teprotumumab